• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of January 1

News
Video

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Number 5: The top 5 most-read rheumatology stories of 2023 included the changing market dynamics in the adalimumab space, including new launches and interchangeability labels, as well as the addition of Stelara and Enbrel to the list of originators up for Medicare price negotiation.

Number 4: The top 5 most-read oncology stories of 2023 include the US market launch of Fylnetra, the sixth pegfilgrastim biosimilar on the market, the FDA approval for an autoinjector pegfilgrastim biosimilar, and more.

Number 3: The top 5 most-read ophthalmology stories of 2023 concerned clinical results, approvals, and launches for ranibizumab and aflibercept biosimilars.

Number 2: The top 5 most-read regulatory stories of 2023 covered the FDA approvals for the first ustekinumab biosimilar and the first subcutaneous infliximab product, as well as other regulatory updates.

Number 1: The regulatory structure of biosimilar development can be safely streamlined and made more efficient and less costly, wrote authors from Sandoz, Fresenius Kabi, Boehringer Ingelheim, and Samsung Bioepis in an opinion article published in BioDrugs.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Here are the top 5 biosimilar articles for the week of July 21, 2025.
Here are the top 5 biosimilar articles for the week of July 14, 2025.
Here are the top 5 biosimilar articles for the week of July 7, 2025.
Here are the top 5 biosimilar articles for the week of June 30, 2025.
Canavan & O’Dell
Here are the top 5 biosimilar articles for the week of June 23, 2025.
Here are the top 5 biosimilar articles for the week of June 16, 2025.
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Here are the top 5 biosimilar articles for the week of June 9, 2025.
Here are the top 5 biosimilar articles for the week of June 2, 2025.
Related Content
© 2025 MJH Life Sciences

All rights reserved.